CatalystMarker
← board

SGP

SpyGlass Pharma, Inc.distress 2/10 · well-funded / low risk
$20.40-1%today-31% from 52w high
spyglasspharma.com68 employeesFounded 2019Aliso Viejo, CABiotechnology
Cardiovascular 1
Lead: Cataract · target Prostaglandin
Revenue
pre-revenue
Liquidity
$239M
Runway
7.3 yrs
Shares 1y
0%

Price & events

-22.7% over 6M
$17.56$23.62$29.68Feb 26Apr 26Jul 261.5Mdilution: 424B4 offering (2026-02-06)rating: HC Wainwright & Co.: Buy (2026-03-10)rating: Citigroup: Buy (2026-03-03)rating: Leerink Partners: Outperform (2026-03-03)rating: Jefferies: Buy (2026-03-03)rating: Stifel: Buy (2026-03-03)
CatalystRating changeDilutionFinancingdashed = today
-0.7%
1D
-1.7%
1W
+3.7%
1M
-13.7%
3M
—
6M
—
1Y
—
2Y
—
5Y
-22.7%
All

Overview

Market Cap
$682.04M
Volume
5.21K
52 Week Range
$17.56 – $29.68
Total Shares
33.43M
Float Shares
6.48M
Short %
11.82%
% Held by Insiders
4.28%
% Held by Institutions
92.39%
RVOL
0.03x

Pipeline stages · 2 programs

Bimatoprost Implant System, Timolol Maleate Ophthalmic Solution, 0.5%
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2029-03-31
Bimatoprost Implant System (High Dose), Bimatoprost Implant System (Low Dose), Timolol MalProstaglandin
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved

Pipeline · 3 trials · 2 upcoming

ReadoutPhaseDrugIndicationEnrollStatus
2029-03-31
Estimated 50%
readout ~2029-06-14
Phase 3Bimatoprost Implant System, Timolol Maleate Ophthalmic Solution, 0.5%Cataract, Glaucoma, Ocular Hypertension—recruiting
2029-05-31
Estimated 50%
readout ~2029-08-14
Phase 3Bimatoprost Implant System, Timolol Maleate Ophthalmic Solution, 0.5%Cataract, Glaucoma, Ocular Hypertension—recruiting
2025-01-31
Phase 1/2Bimatoprost Implant System (High Dose), Bimatoprost Implant System (Low Dose), Timolol MalCataract, Glaucoma, Ocular Hypertension201active not recruiting

Catalyst news & presentations · 1

Approved drugs (0)

  • none — clinical-stage

Capital structure — dilution & financing

Shares out: 33,433,355 · 1 offerings/1y · 0 PIPEs
  • 2026-02-06424B4offering
  • 2026-01-30EFFECTshelf_effective
  • 2026-01-29S-1/Ashelf_registration
  • 2026-01-16S-1shelf_registration
🔒 Positioning — Pro
Short interest / days-to-cover, insider buys & sells.
Upgrade to Pro
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to Pro

Wall St ratings

no consensus
  • 2026-03-10HC Wainwright & Co.Buy
  • 2026-03-03CitigroupBuy
  • 2026-03-03Leerink PartnersOutperform
  • 2026-03-03JefferiesBuy
  • 2026-03-03StifelBuy

Competitors — Prostaglandin

  • ABBVAbbVie Inc.$451.1B · D2
  • AMRXAmneal Pharmaceuticals, Inc.$5.7B · D1

Recent news

Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.